Home >
AEPSO Argentina launches digital map to find people with psoriasis in the country
2015/04/09 - News from patients associations
Psoriasis, recognised today by the World Health Organization (WHO) as a painful and incapacitating non communicable chronic disease, affects more than 800 000 Argentineans. AEPSO (Asociación Civil para el Enfermo de Psoriasis) celebrates its 10th anniversary raising awareness and supporting the rights of the patients. In order to better know what is going on with the disease in Argentina and to reach out the different communities, AEPSO has launched an interactive digital map, accessible through Facebook, that aims to identify and connect all psoriasis patients in each corner of the country.
Silvia Fernández Barrio, president and founder of AEPSO, has acknowledged that social networks have contributed to show unknown realities that they wish to work on for the benefit of the patients: “This is why this map came about, a tool that will give precise information where persons with psoriasis in Argentina live, and thus better help each one of them, guide them to informed professionals and to centres where they can get the treatment they need, as well as to create ties among patients going through the same experience in their community. In a territory as vast and with different realities we have to take advantage of technology as an opportunity to shorten distance and time”.
During the next 10 years, Beatriz Larrea, Executive Director of AEPSO, said that “we would like to achieve a presence of groups of people with psoriasis in every region of the country. That there are patients gathering, giving their time and sharing their experiences and knowledge in order to help others to better cope with their reality”.
One of the greatest obstacles that a psoriasis patients still faces is ignorance. There are patients that do not see a doctor because of the old prejudice that this is a disease that there is nothing you can do, so they give up. “Nothing could be farther from the truth”, exclaimed Silvia Fernández Barrio, adding “those people we must reach them through AEPSO; so that they know who we are, that we are here to help them, guide them, provide them with information and suggest where they can start to treat themselves. Their life can change, and is going to change”.
“We strive to achieve that no patient across the country lives withouth diagnosis or treatment; we have a lot of work ahead of us, but we know this is the way”, added the president of AEPSO.
You can find the map at:
https://www.facebook.com/pages/AEPSO/103448854973?sk=app_1497274527196166
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Melissa officinalis ssp. altissima extracts: A therapeutic approach targeting psoriasis in mice.
J Ethnopharmacol.
2020 Jan 10, 246:112208.
Melissa officinalis L., commonly known as lemon balm, is one of the most well known edible and medicinal plants of the Lamiaceae family. It is quoted in almost all known medical treatises, from Antiquity up to modern era, such as Corpus Hippocraticum, Dioscorides' De Materia Medica and later on in medieval medical manuscripts and Pharmacopoeias. Actually, it is widely used as herbal medicine for the relief of mild symptoms of mental stress, to aid sleep and for symptomatic treatment of mild (...)
see on pubmed
Musa acuminata and its bioactive metabolite 5-Hydroxymethylfurfural mitigates quorum sensing (las and rhl) mediated biofilm and virulence production of nosocomial pathogen Pseudomonas aeruginosa in vitro.
J Ethnopharmacol.
2020 Jan 10, 246:112242.
Musa acuminata, a tropical plant belongs to the family Musaceae. The fruit peels of this plant have been well documented for their therapeutic value in Asia and Africa. It has also been previously reported for numerous biological applications such as antimicrobial, antioxidant, itching, psoriasis and anti-diarrheal activities. Moreover, M. acuminata peels have been well known for its anti-healing and antiseptic properties and most commonly used for healing wounds and heat burns in South (...)
see on pubmed
Kan-Lu-Hsiao-Tu-Tan, a traditional Chinese medicine formula, inhibits human neutrophil activation and ameliorates imiquimod-induced psoriasis-like skin inflammation.
J Ethnopharmacol.
2020 Jan 10, 246:112246.
Kan-Lu-Hsiao-Tu-Tan (KLHTT) is a popular traditional Chinese medicine for treating various inflammatory diseases.
see on pubmed
on Atopic Dermatitis
What's new in atopic eczema? An analysis of systematic reviews published in 2017. Part 2: epidemiology, aetiology and risk factors.
Clin. Exp. Dermatol..
2019 Dec , 44, (8):868-873.
This article forms part of a series of annual updates that summarizes the evidence base for atopic eczema (AE). It provides a summary of key findings from 28 systematic reviews that were published or indexed during 2017, and focuses on the epidemiology, aetiology and risk factors of AE. AE is the largest single contributor to morbidity associated with skin disease worldwide, once mortality has been excluded. There is a high prevalence of sleep disturbance in individuals with AE and they (...)
see on pubmed
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Artif Cells Nanomed Biotechnol.
2019 Dec , 47, (1):3540-3547.
Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of ( Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual Drops (...)
see on pubmed
Double blinded, vehicle controlled, crossover study on the efficacy of a topical endocannabinoid membrane transporter inhibitor in atopic Beagles.
Arch. Dermatol. Res..
2019 Dec , 311, (10):795-800.
The endocannabinoid system is important for skin homeostasis and alterations are linked to inflammatory diseases like atopic dermatitis (AD). Importantly, activation of cannabinoid receptor CB2 decreases pruritus and inflammation in mouse models. Reduction of inactivation of endogenous cannabinoids could, therefore, be a therapeutic option for AD. Dogs spontaneously develop AD, which closely mimics the human disease making them suitable to test new therapies. Our study aimed to test the (...)
see on pubmed
